These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16224086)

  • 1. Applying a phase II futility study design to therapeutic stroke trials.
    Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
    Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
    Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
    Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of futility.
    Levin B
    Stroke; 2005 Nov; 36(11):2331-2. PubMed ID: 16224096
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A method to determine stroke trial success using multidimensional pooled control functions.
    Mandava P; Kent TA
    Stroke; 2009 May; 40(5):1803-10. PubMed ID: 19286598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data.
    ; Phan TG; Donnan GA; Davis SM; Byrnes G
    Stroke; 2006 Oct; 37(10):2521-5. PubMed ID: 16931782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint.
    Whitehead J; Jaki T
    Stat Med; 2009 Feb; 28(5):828-47. PubMed ID: 19061203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel methodologic approaches to phase I, II, and III trials.
    Yeatts SD
    Stroke; 2013 Jun; 44(6 Suppl 1):S116-8. PubMed ID: 23709704
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal two-stage log-rank test for randomized phase II clinical trials.
    Kwak M; Jung SH
    J Biopharm Stat; 2017; 27(4):639-658. PubMed ID: 27050043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
    Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
    Trials; 2024 May; 25(1):312. PubMed ID: 38725072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.